Patents Represented by Attorney Joel B. German

Find this attorney in the Justia Lawyer Directory

  • Cyclosporin compositions
    Patent number: 8288348
    Abstract: Cyclosporin A compositions are disclosed herein comprising an oil and a surfactant. These are useful in the treatment of dry eye disease.
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: October 16, 2012
    Assignee: Allergan, Inc.
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
  • Compositions and methods for treating spasticity
    Patent number: 8217059
    Abstract: Disclosed are methods of treating spasticity by administering to a patient in need of such treatment a compound having the following formula:
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: July 10, 2012
    Assignee: Allergan, Inc.
    Inventors: Daniel W. Gil, John E. Donello
  • Methods for treating anxiety
    Patent number: 8211917
    Abstract: Disclosed are methods of treating anxiety by administering to a patient in need of such treatment a compound having the following formula (I).
    Type: Grant
    Filed: July 8, 2008
    Date of Patent: July 3, 2012
    Assignee: Allergan, Inc.
    Inventors: John E. Donello, Lauren M. B. Luhrs
  • Methods for treating cognitive disorders
    Patent number: 8173683
    Abstract: Disclosed herein are methods of treating a patient suffering a cognitive disorder.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: May 8, 2012
    Assignees: Allergan, Inc., ExonHit Therapeutics SA
    Inventors: John E. Donello, Fabien J. Schweighoffer, Lauren M. Luhrs
  • 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity
    Patent number: 8168631
    Abstract: Compounds according to the formula below are disclosed herein: Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Grant
    Filed: February 3, 2009
    Date of Patent: May 1, 2012
    Assignee: Allergan, Inc.
    Inventors: Bertrand Leblond, Eric Beausoleil, Thierry Taverne, John E. Donello, Rong Yang, Cédric Chauvignac
  • Treating pain using selective antagonists of persistent sodium current
    Patent number: 8153645
    Abstract: The present invention provides methods of treating chronic pain in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.
    Type: Grant
    Filed: August 1, 2006
    Date of Patent: April 10, 2012
    Assignee: Allergan, Inc.
    Inventors: George R. Ehring, Joseph S. Adorante, John E. Donello, Larry A. Wheeler, Thomas Malone
  • Compounds having analgesic and/or immunostimulant activity
    Patent number: 8153666
    Abstract: The compounds shown by their structural formulas in the specification have analgesic and or immunostimulant activity in mammals.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: April 10, 2012
    Assignee: Allergan, Inc.
    Inventors: Bertrand Leblond, Eric Beausoleil, Thierry Taverne, John E. Donello
  • Kinase inhibitors
    Patent number: 8143410
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Grant
    Filed: January 5, 2009
    Date of Patent: March 27, 2012
    Assignee: Allergan, Inc.
    Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. Devries, Jeffrey L. Edelman, Julie A. Wurster
  • Treating neurological disorders using selective antagonists of persistent sodium current
    Patent number: 8124612
    Abstract: The present invention provides methods of treating neurological disorders in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: February 28, 2012
    Assignee: Allergan, Inc.
    Inventors: George R. Ehring, Joseph S. Adorante, Larry A. Wheeler, Thomas Malone, Scott M. Whitcup
  • Sulfoximines as kinase inhibitors
    Patent number: 7915443
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: March 29, 2011
    Assignee: Allergan, Inc.
    Inventors: Julie A. Wurster, Clarence Eugene Hull, III, Richard C. Yee, Sougato Boral, Shimiao Wang, Thomas C. Malone
  • Therapeutic methods using cyclosporine components
    Patent number: 7902155
    Abstract: Methods of treating humans or animals having dysfunctional oral mucosal tissue are disclosed which include topically administering cyclosporine A, salts thereof and/or mixtures thereof in an oral cavity of the human or animal.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: March 8, 2011
    Assignee: Allergan, Inc.
    Inventors: Michael E. Stern, David Power
  • Methods of treating blepharospasm using cyclosporine components
    Patent number: 7655625
    Abstract: Methods of treating humans or animals afflicted with primary blepharospasm, for example, benign essential blepharospasm, or secondary blepharospasm not caused by an ocular surface disease or condition, are component to a human or animal so afflicted.
    Type: Grant
    Filed: February 12, 2007
    Date of Patent: February 2, 2010
    Assignee: Allergan, Inc.
    Inventor: Mitchell F. Brin
  • Methods for detecting receptor modulator activity
    Patent number: 7655396
    Abstract: Disclosed herein are methods of screening compounds that modulate G-protein coupled receptors. The assays are performed at temperatures of between about 25° C. and 40° C.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: February 2, 2010
    Assignee: Allergan, Inc.
    Inventors: Karen M. Kedzie, Sandhya Rao, Daniel W. Gil, John E. Donello
  • Treatment with cyclosporin A
    Patent number: 7557082
    Abstract: Disclosed herein is a method comprising administering cyclosporin A topically to an eye of a person for the purpose of treating or preventing loss of vision from keratoconus.
    Type: Grant
    Filed: March 1, 2007
    Date of Patent: July 7, 2009
    Assignee: Allergan, Inc.
    Inventor: Rhett M. Schiffman
  • Kinase inhibitors for the treatment of disease
    Patent number: 7531665
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: April 20, 2004
    Date of Patent: May 12, 2009
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Michael E. Garst, Xialing Guo, Jonathan J. Hebert, Thomas Malone, Julie A. Wurster, Clarence Eugene Hull, III
  • Indol kinase inhibitors
    Patent number: 7439371
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: July 11, 2006
    Date of Patent: October 21, 2008
    Assignee: Allergan, Inc.
    Inventors: Julie A. Wurster, Richard C. Yee
  • 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
    Patent number: 7414054
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: November 15, 2005
    Date of Patent: August 19, 2008
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Julie A. Wurster, Edward H. Wang, Thomas Malone
  • 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
    Patent number: 7393870
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: November 17, 2005
    Date of Patent: July 1, 2008
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Julie A. Wurster
  • Methods and compositions for alleviating pain
    Patent number: 7345065
    Abstract: The present invention provides a method for the long-term relief of chronic pain in a subject by activating in the subject an analgesic ?-adrenergic receptor in the absence of ?-2A receptor activation over a period of at least three days, such that relief of chronic pain is maintained in the absence of continued activation of said receptor. The analgesic ?-adrenergic receptor can be, for example, the ?-2B receptor.
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: March 18, 2008
    Assignee: Allergan, Inc.
    Inventors: Daniel W. Gil, John E. Donello
  • Human prostaglandin FP receptor variants and methods of using same
    Patent number: 7320871
    Abstract: The invention provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 17, 18, 19, 20, 21, 22, 23, 24, or 25. The invention also provides an isolated polypeptide containing an amino acid sequence having at least 50% amino acid identity with SEQ ID NO: 14 and an amino acid sequence of SEQ ID NO: 17, 18, 19, 20, 21, 22, 23, 24, or 25, or a conservative variant thereof. The invention further provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, or 12. The invention also provides a method for identifying a compound that modulates a FP receptor variant by contacting an isolated FP receptor variant or a FP receptor variant over-expressed in a genetically engineered cell with a compound and determining the level of an indicator which correlates with modulation of a FP receptor variant, where an alteration in the level of the indicator as compared to a control level indicates that the compound is a compound that modulates the FP receptor variant.
    Type: Grant
    Filed: July 14, 2003
    Date of Patent: January 22, 2008
    Assignee: Allergan, Inc.
    Inventors: Yanbin Liang, David F. Woodward